Strategies to Overcome Antimicrobial Resistance in Nosocomial Infections, A Review and Update
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Nosocomial infections, also known as healthcare-associated infections, are a signif-icant global concern due to their strong association with high mortality and morbidity in both developed and developing countries. These infections are caused by a variety of pathogens, particularly the ESKAPE group of bacteria, which includes the six pathogens Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudo-monas aeruginosa, and Enterobacter spp. These bacteria have demonstrated noteworthy re-sistance to different antibiotics. Antimicrobial resistance mechanisms can manifest in various forms, including restricting drug uptake, modifying drug targets, inactivating drugs, active drug efflux, and biofilm formation. Accordingly, various strategies have been developed to combat antibiotic-resistant bacteria. These strategies encompass the development of new antibiotics, the utilization of bacterio-phages that specifically target these bacteria, antimicrobial combination therapy and the use of peptides or enzymes that target the genomes or essential proteins of resistant bacteria. Among promising approaches to overcome antibiotic resistance, the CRISPR/Cas system stands out and offers many advantages. This system enables precise and efficient editing of genetic material at specific locations in the genome. Functioning as a bacterial "adaptive im-mune system," the CRISPR/Cas system recognizes, degrades, and remembers foreign DNA sequences through the use of spacer DNA segments that are transcribed into CRISPR RNAs (crRNA). This paper has focused on nosocomial infections, specifically the pathogens involved in hospi-tal infections, the mechanisms underlying bacterial resistance, and the strategies currently em-ployed to address this issue. Special emphasis has been placed on the application of CRISPR/Cas technology for overcoming antimicrobial resistance.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Infectious disorders drug targets - (2024) vom: 26. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bakhtiyari, Nasim [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Revised 29.01.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/0118715265276529231214105423 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36775102X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36775102X | ||
| 003 | DE-627 | ||
| 005 | 20240129232316.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240129s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/0118715265276529231214105423 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1274.xml |
| 035 | |a (DE-627)NLM36775102X | ||
| 035 | |a (NLM)38284691 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bakhtiyari, Nasim |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Strategies to Overcome Antimicrobial Resistance in Nosocomial Infections, A Review and Update |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 29.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Nosocomial infections, also known as healthcare-associated infections, are a signif-icant global concern due to their strong association with high mortality and morbidity in both developed and developing countries. These infections are caused by a variety of pathogens, particularly the ESKAPE group of bacteria, which includes the six pathogens Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudo-monas aeruginosa, and Enterobacter spp. These bacteria have demonstrated noteworthy re-sistance to different antibiotics. Antimicrobial resistance mechanisms can manifest in various forms, including restricting drug uptake, modifying drug targets, inactivating drugs, active drug efflux, and biofilm formation. Accordingly, various strategies have been developed to combat antibiotic-resistant bacteria. These strategies encompass the development of new antibiotics, the utilization of bacterio-phages that specifically target these bacteria, antimicrobial combination therapy and the use of peptides or enzymes that target the genomes or essential proteins of resistant bacteria. Among promising approaches to overcome antibiotic resistance, the CRISPR/Cas system stands out and offers many advantages. This system enables precise and efficient editing of genetic material at specific locations in the genome. Functioning as a bacterial "adaptive im-mune system," the CRISPR/Cas system recognizes, degrades, and remembers foreign DNA sequences through the use of spacer DNA segments that are transcribed into CRISPR RNAs (crRNA). This paper has focused on nosocomial infections, specifically the pathogens involved in hospi-tal infections, the mechanisms underlying bacterial resistance, and the strategies currently em-ployed to address this issue. Special emphasis has been placed on the application of CRISPR/Cas technology for overcoming antimicrobial resistance | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Nosocomial infections; Drug resistance; CRISPR/Cas system; bacteriophage; antimicrobial peptide; ESKAPE. | |
| 700 | 1 | |a Farajnia, Safar |e verfasserin |4 aut | |
| 700 | 1 | |a Ghasemali, Samaneh |e verfasserin |4 aut | |
| 700 | 1 | |a Farajnia, Sahar |e verfasserin |4 aut | |
| 700 | 1 | |a Pourmohammad, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Saeidvafa, Shabnam |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Infectious disorders drug targets |d 2006 |g (2024) vom: 26. Jan. |w (DE-627)NLM163628408 |x 2212-3989 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:26 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/0118715265276529231214105423 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 26 |c 01 | ||